596 related articles for article (PubMed ID: 22438231)
21. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.
Krieger CC; Neumann S; Place RF; Marcus-Samuels B; Gershengorn MC
J Clin Endocrinol Metab; 2015 Mar; 100(3):1071-7. PubMed ID: 25485727
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy.
Jyonouchi SC; Valyasevi RW; Harteneck DA; Dutton CM; Bahn RS
Thyroid; 2001 Oct; 11(10):929-34. PubMed ID: 11716039
[TBL] [Abstract][Full Text] [Related]
23. Basic Fibroblast Growth Factor Induces Adipogenesis in Orbital Fibroblasts: Implications for the Pathogenesis of Graves' Orbitopathy.
Schrijver B; Kooiman MA; Kasteleijn E; van Holten-Neelen C; Virakul S; Paridaens D; Peeters RP; van Hagen PM; Dalm VASH; Dik WA
Thyroid; 2019 Mar; 29(3):395-404. PubMed ID: 30724135
[TBL] [Abstract][Full Text] [Related]
24. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody.
Kumar S; Iyer S; Bauer H; Coenen M; Bahn RS
J Clin Endocrinol Metab; 2012 May; 97(5):1681-7. PubMed ID: 22399503
[TBL] [Abstract][Full Text] [Related]
25. Evidence for protein and mRNA TSHr expression in fibroblasts from patients with thyroid-associated ophthalmopathy (TAO) after adipocytic differentiation.
Agretti P; De Marco G; De Servi M; Marcocci C; Vitti P; Pinchera A; Tonacchera M
Eur J Endocrinol; 2005 May; 152(5):777-84. PubMed ID: 15879364
[TBL] [Abstract][Full Text] [Related]
26. Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.
Krieger CC; Kahaly GJ; Azam A; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Thyroid; 2022 Jan; 32(1):90-96. PubMed ID: 34714162
[No Abstract] [Full Text] [Related]
27. The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.
Virakul S; Dalm VA; Paridaens D; van den Bosch WA; Hirankarn N; van Hagen PM; Dik WA
Graefes Arch Clin Exp Ophthalmol; 2014 Jul; 252(7):1101-9. PubMed ID: 24874745
[TBL] [Abstract][Full Text] [Related]
28. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
[TBL] [Abstract][Full Text] [Related]
29. EZH2 as a major histone methyltransferase in PDGF-BB-activated orbital fibroblast in the pathogenesis of Graves' ophthalmopathy.
Visamol S; Palaga T; Saonanon P; Pruksakorn V; Hirankarn N; van Hagen PM; Dik WA; Virakul S
Sci Rep; 2024 Apr; 14(1):7947. PubMed ID: 38575707
[TBL] [Abstract][Full Text] [Related]
30. Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy.
Bahn RS
Thyroid; 2002 Mar; 12(3):193-5. PubMed ID: 11952038
[TBL] [Abstract][Full Text] [Related]
31. A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts.
Neumann S; Pope A; Geras-Raaka E; Raaka BM; Bahn RS; Gershengorn MC
Thyroid; 2012 Aug; 22(8):839-43. PubMed ID: 22784331
[TBL] [Abstract][Full Text] [Related]
32. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
Wiersinga WM
J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
[TBL] [Abstract][Full Text] [Related]
33. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
[TBL] [Abstract][Full Text] [Related]
34. Pathogenic Phenotype of Adipogenesis and Hyaluronan in Orbital Fibroblasts From Female Graves' Orbitopathy Mouse Model.
Görtz GE; Moshkelgosha S; Jesenek C; Edelmann B; Horstmann M; Banga JP; Eckstein A; Berchner-Pfannschmidt U
Endocrinology; 2016 Oct; 157(10):3771-3778. PubMed ID: 27552248
[TBL] [Abstract][Full Text] [Related]
35. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model.
Diana T; Ungerer M; Wüster C; Faßbender J; Li Z; Reimann A; Holthoff HP; Kanitz M; Kahaly GJ
J Autoimmun; 2021 Aug; 122():102666. PubMed ID: 34144327
[TBL] [Abstract][Full Text] [Related]
36. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy.
Kumar S; Nadeem S; Stan MN; Coenen M; Bahn RS
J Mol Endocrinol; 2011 Jun; 46(3):155-63. PubMed ID: 21321093
[TBL] [Abstract][Full Text] [Related]
37. Complete inhibition of rhTSH-, Graves' disease IgG-, and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist.
van Zeijl CJ; van Koppen CJ; Surovtseva OV; de Gooyer ME; Plate R; Conti P; Karstens WJ; Timmers M; Saeed P; Wiersinga WM; Miltenburg AM; Fliers E; Boelen A
J Clin Endocrinol Metab; 2012 May; 97(5):E781-5. PubMed ID: 22419705
[TBL] [Abstract][Full Text] [Related]
38. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves' orbitopathy.
Zhang L; Grennan-Jones F; Lane C; Rees DA; Dayan CM; Ludgate M
J Clin Endocrinol Metab; 2012 Feb; 97(2):653-62. PubMed ID: 22162480
[TBL] [Abstract][Full Text] [Related]
39. Histone Deacetylase 4 Controls Extracellular Matrix Production in Orbital Fibroblasts from Graves' Ophthalmopathy Patients.
Ekronarongchai S; Palaga T; Saonanon P; Pruksakorn V; Hirankarn N; van Hagen PM; Dik WA; Virakul S
Thyroid; 2021 Oct; 31(10):1566-1576. PubMed ID: 34235979
[No Abstract] [Full Text] [Related]
40. The orbital fibroblast: a key player and target for therapy in graves' ophthalmopathy.
van Steensel L; Dik WA
Orbit; 2010 Aug; 29(4):202-6. PubMed ID: 20812837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
